News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Becton Dickinson (BDX) is back in focus after announcing a collaboration with EMS to support the launch of a semaglutide therapy in Brazil. The …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients. FRANKLIN LAKES, N.J. and SÃO PAULO, July 29, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%BD (Becton, Dickinson and Company) and EMS, a leading Brazilian pharmaceutical company, have collaborated to launch an EMS semaglutide therapy in Brazil using the BD Vystra™ Injection Pen platform. This partnership aims to enhance access to GLP-1 treatments for chronic metabolic diseases like obesity …
This article provides a detailed profile of the BDX.GJ bond issued by Becton, Dickinson & Co. It outlines key metrics such as the issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. The bond's profile is focused on the …
Becton, Dickinson & Co. (BDX) has an estimated 69,784 total employees worldwide as of March 2026, marking a 5.3% decline from 2023. Despite this reduction in headcount, the company is actively hiring, with 3,619 active job postings in 2026, a 33.8% increase from the …
BD (Becton, Dickinson and Company) has announced that its Board of Directors declared a quarterly dividend of $1.05 per common share. This dividend is payable on September 30, 2026, to shareholders of record as of September 9, 2026. The indicated annual dividend rate is …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Becton, Dickinson and Company (BDX) saw its stock surge 5.4% on Tuesday, July 28, 2026, closing at $167.58, as part of a broad rally that uplifted the entire medical device sector. This coordinated move, which also saw gains from Abbott Laboratories, Stryker, and Intuitive …
Becton, Dickinson (BDX) shares rose by 3.9% after UBS initiated coverage with a Buy rating and a $190 price target, citing a cleaner post-Waters transaction outlook. The positive sentiment is also fueled by recent profit guidance increases, aggressive share repurchases, and anticipation of its …
Michael Feld, Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co. (NASDAQ:BDX), sold 75 shares of the company's common stock for a total of $11,784, priced at $157.13 per share. This transaction was conducted on July 27, 2026, under a Rule …
Becton Dickinson & Co's EVP and Chief Revenue Officer, Michael Feld, sold 75 shares of common stock on July 27, 2026, at $157.13 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on February 7, 2025. After the sale, Feld …
UBS has initiated coverage on Becton Dickinson & Co. (NYSE:BDX) with a buy rating and a price target of $190.00, citing the company's de-rated valuation and anticipated mid-single-digit long-term growth. The firm believes market concerns about slowing growth and inflation are overstated, highlighting BD's …
Becton Dickinson (BDX) is under renewed scrutiny following the announcement of a long-serving executive's retirement, prompting a reassessment of the company's valuation. Despite recent share price choppiness and a year-to-date decline, the stock is currently trading below both its intrinsic and analyst-estimated fair value …
Luxor Capital Group LP recently acquired a new stake of 247,240 shares in Becton, Dickinson and Company (NYSE:BDX), valued at approximately $38.9 million, making it their 10th largest holding. The acquisition follows Becton, Dickinson's strong first-quarter earnings, which surpassed analyst expectations for both EPS …
The Public Employees Retirement System of Ohio increased its stake in Becton, Dickinson and Company (BDX) by 9.9% in the first quarter, now holding 128,930 shares valued at approximately $20.3 million. BDX shares were up 2.2% on Friday, with a market capitalization of $43.06 …
Sei Investments Co. has increased its stake in Becton, Dickinson and Company (BDX) by 13.7% in Q1, acquiring an additional 36,488 shares, bringing its total holdings to $47.7 million. Despite Becton, Dickinson reporting better-than-expected quarterly earnings and raising its FY 2026 guidance, Wall Street …
Arrowstreet Capital Limited Partnership increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 19.4% in the first quarter, acquiring an additional 162,521 shares. This brings their total holding to 1,002,375 shares valued at approximately $157.6 million. Other major institutional investors like Vanguard Group …
Archon Partners LLC acquired a new position in Becton, Dickinson and Company (NYSE:BDX) during the first quarter, purchasing 71,000 shares valued at approximately $11.16 million. This investment makes BDX the 27th largest holding for Archon Partners LLC, representing 1.3% of their holdings. Other institutional …
Dr. Michael “Mike” Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments at BD (Becton, Dickinson and Company), is retiring after more than 20 years with the company, effective October 2. During his tenure, Garrison held several leadership roles …
Dimensional Fund Advisors LP significantly reduced its stake in Becton, Dickinson and Company (BDX) by 5.6% during the first quarter, now holding 2,271,757 shares valued at $357.1 million. This reduction comes amid other institutional investor activity and insider selling by CEO Thomas E. Polen, …
Becton Dickinson (BDX) stock is stable as investors evaluate the medical technology supplier's recent fiscal performance, which shows steady revenue growth, improving margins, and strong cash flow. The company reported revenue near $20 billion and consistent profit generation, supported by diversified segments including medical …
Rapid growth reflects seismic shift toward greater use of AI across the MedTech industry BOSTON, July 22, 2026--(BUSINESS WIRE)--AcuityMD, the AI platform for MedTech, today announced it is now trusted by more than 500 medical device (MedTech) companies, including 16 of the top 20, …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%FRANKLIN LAKES, N.J., July 22, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Becton Dickinson & Co. (BDX) stock fell by 2.33% on Monday, closing at $154.48, which was part of a larger downturn in the stock market where the S&P 500 Index and Dow Jones Industrial Average also declined. This marked the second consecutive day of …
Becton, Dickinson and Company (BDX) is a healthcare stalwart with a $43.58 billion market capitalization, offering stability and growth potential. Its current stock price of $158.17, with an average analyst target price of $179.36, suggests a 13.4% upside. Strong financial fundamentals, a positive analyst …
Becton Dickinson (BDX) stock is currently reflecting a balance between defensive healthcare exposure and post-pandemic normalization, with investors focusing on recent earnings, cash flow, and market demand for medical devices. The company's diverse portfolio spans medication management, diagnostics, and interventional products, which are key …
Becton Dickinson (BDX) has seen its stock fall 18% over three years, appearing undervalued by about 21.5% based on a Discounted Cash Flow (DCF) model, which points to an intrinsic value of $204 per share. However, its P/E ratio of 26.8x suggests it is …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Becton Dickinson (ISIN US0718131099) is a global medical technology company whose stock is supported by a diversified portfolio of medical devices and diagnostics. The company's recurring revenue model, driven by essential consumables and instruments, benefits from stable demand in healthcare, making it appealing to …
Search by ticker symbol or company name and select a result to open its chart.